Joseph Letourneau1,2,3, Flor Juarez-Hernandez4, Kaitlyn Wald4,5, Salustiano Ribeiro4, Ange Wang4, Charles E McCulloch6, Evelyn Mok-Lin4, Milana Dolezal7, A Jo Chien8, Marcelle I Cedars4, Mitchell Rosen4. 1. Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco School of Medicine, San Francisco, CA, USA. Joseph.letourneau@hsc.utah.edu. 2. Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City, UT, USA. Joseph.letourneau@hsc.utah.edu. 3. Utah Center for Reproductive Medicine, 675 Arapeen Drive, Suite 205, Salt Lake City, UT, 84108, USA. Joseph.letourneau@hsc.utah.edu. 4. Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco School of Medicine, San Francisco, CA, USA. 5. Seattle Reproductive Medicine, Seattle, WA, USA. 6. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA. 7. Hematology and Oncology, California Pacific Medical Center Research Institute, San Francisco, CA, USA. 8. Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, CA, USA.
Abstract
PURPOSE: To determine whether concomitant tamoxifen 20 mg with gonadotropins (tamoxifen-gonadotropin) versus letrozole 5 mg with gonadotropins (letrozole-gonadotropin) affects mature oocyte yield. METHODS: Open-label, single-institution, randomized trial. Inclusion criteria included the following: females, ages 18-44 years old, with new diagnosis of non-metastatic breast cancer, who were undergoing fertility preservation with either oocyte or embryo cryopreservation. Those with estrogen-receptor-positive (ER+) breast cancer were randomized to tamoxifen-gonadotropin or letrozole-gonadotropin. Another group with estrogen-receptor-negative (ER-) breast cancer was recruited, as a prospectively collected comparison arm who took neither letrozole nor tamoxifen (gonadotropin only). The primary outcome was the number of mature oocytes obtained from the cycle. The randomized groups were powered to detect a difference of three or more mature oocytes. RESULTS: Forty-five patients were randomized to tamoxifen-gonadotropin and fifty-one to letrozole-gonadotropin. Thirty-eight patients completed gonadotropin only. Age, antral follicle count, and body mass index were similar between the randomized groups. Our primary outcome of mature oocyte yield was similar between the tamoxifen-gonadotropin and letrozole-gonadotropin groups (12±8.6 vs. 11.6±7.5, p=0.81, 95%CI of difference =-2.9 to 3.7). In a pre-specified secondary comparison, mature oocyte yield was also similar with tamoxifen-gonadotropin or letrozole-gonadotropin versus gonadotropin only (12±8.6 vs. 11.6±7.5 vs. 12.4±7.2). There were no serious adverse events in any of the groups. CONCLUSIONS: Tamoxifen-gonadotropin and letrozole-gonadotropin produced a similar number of mature oocytes. Women who received either tamoxifen-gonadotropin or letrozole-gonadotropin had a similar number of oocytes to the gonadotropin-only group. TRIAL REGISTRATION: NCT03011684 (retrospectively registered 1/5/2017, after 9% enrolled).
PURPOSE: To determine whether concomitant tamoxifen 20 mg with gonadotropins (tamoxifen-gonadotropin) versus letrozole 5 mg with gonadotropins (letrozole-gonadotropin) affects mature oocyte yield. METHODS: Open-label, single-institution, randomized trial. Inclusion criteria included the following: females, ages 18-44 years old, with new diagnosis of non-metastatic breast cancer, who were undergoing fertility preservation with either oocyte or embryo cryopreservation. Those with estrogen-receptor-positive (ER+) breast cancer were randomized to tamoxifen-gonadotropin or letrozole-gonadotropin. Another group with estrogen-receptor-negative (ER-) breast cancer was recruited, as a prospectively collected comparison arm who took neither letrozole nor tamoxifen (gonadotropin only). The primary outcome was the number of mature oocytes obtained from the cycle. The randomized groups were powered to detect a difference of three or more mature oocytes. RESULTS: Forty-five patients were randomized to tamoxifen-gonadotropin and fifty-one to letrozole-gonadotropin. Thirty-eight patients completed gonadotropin only. Age, antral follicle count, and body mass index were similar between the randomized groups. Our primary outcome of mature oocyte yield was similar between the tamoxifen-gonadotropin and letrozole-gonadotropin groups (12±8.6 vs. 11.6±7.5, p=0.81, 95%CI of difference =-2.9 to 3.7). In a pre-specified secondary comparison, mature oocyte yield was also similar with tamoxifen-gonadotropin or letrozole-gonadotropin versus gonadotropin only (12±8.6 vs. 11.6±7.5 vs. 12.4±7.2). There were no serious adverse events in any of the groups. CONCLUSIONS: Tamoxifen-gonadotropin and letrozole-gonadotropin produced a similar number of mature oocytes. Women who received either tamoxifen-gonadotropin or letrozole-gonadotropin had a similar number of oocytes to the gonadotropin-only group. TRIAL REGISTRATION: NCT03011684 (retrospectively registered 1/5/2017, after 9% enrolled).
Authors: M Yi; L Huo; K B Koenig; E A Mittendorf; F Meric-Bernstam; H M Kuerer; I Bedrosian; A U Buzdar; W F Symmans; J R Crow; M Bender; R R Shah; G N Hortobagyi; K K Hunt Journal: Ann Oncol Date: 2014-02-20 Impact factor: 32.976
Authors: Michael P Diamond; Richard S Legro; Christos Coutifaris; Ruben Alvero; Randal D Robinson; Peter Casson; Gregory M Christman; Joel Ager; Hao Huang; Karl R Hansen; Valerie Baker; Rebecca Usadi; Aimee Seungdamrong; G Wright Bates; R Mitchell Rosen; Daniel Haisenleder; Stephen A Krawetz; Kurt Barnhart; J C Trussell; Dana Ohl; Yufeng Jin; Nanette Santoro; Esther Eisenberg; Heping Zhang Journal: N Engl J Med Date: 2015-09-24 Impact factor: 91.245
Authors: Halle C F Moore; Joseph M Unger; Kelly-Anne Phillips; Frances Boyle; Erika Hitre; David Porter; Prudence A Francis; Lori J Goldstein; Henry L Gomez; Carlos S Vallejos; Ann H Partridge; Shaker R Dakhil; Agustin A Garcia; Julie Gralow; Janine M Lombard; John F Forbes; Silvana Martino; William E Barlow; Carol J Fabian; Lori Minasian; Frank L Meyskens; Richard D Gelber; Gabriel N Hortobagyi; Kathy S Albain Journal: N Engl J Med Date: 2015-03-05 Impact factor: 91.245
Authors: M B Zelinski-Wooten; D L Hess; W L Baughman; T A Molskness; D P Wolf; R L Stouffer Journal: J Clin Endocrinol Metab Date: 1993-04 Impact factor: 5.958
Authors: Eva M E Balkenende; Taghride Dahhan; Catharina C M Beerendonk; Kathrin Fleischer; Dominic Stoop; Annelies M E Bos; Cornelis B Lambalk; Roel Schats; Jesper M J Smeenk; Leonie A Louwé; Astrid E P Cantineau; Jan Peter de Bruin; Sabine C Linn; Fulco van der Veen; Madelon van Wely; Mariëtte Goddijn Journal: Hum Reprod Date: 2022-07-30 Impact factor: 6.353